Testing a DNA marker in lymphoma-related HLH
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial looks for a DNA marker in people with HLH caused by lymphoma. It may help doctors better confirm the cause of HLH and guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are able and willing to give informed consent for the study
- You are 18 years or older
- You have a confirmed diagnosis of HLH
- For this current HLH episode, you started high-dose steroids and/or other anti-cancer treatment (SACT) within the last 72 hours (anakinra alone doesn’t count as SACT)
- Your HLH is linked to lymphoma, or could be—either newly diagnosed or recurrent/relapsed HLH with known or suspected lymphoma
- Your HLH does not already have a known cause other than cancer (a non-cancer cause must not be the known reason)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the bacteria in your body (your microbiome) and how they might be connected to blood cancers and a rare condition called HLH. By joining, you help researchers learn more about these diseases, which may lead to better treatments in the future.
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This study follows adults who have findings that suggest HLH, a serious immune problem. It may help doctors better understand the condition by tracking patients over time and comparing symptoms and test results.
This study is for people with hemophagocytic lymphohistiocytosis (HLH), a condition where the immune system becomes overactive. Researchers want to collect medical data and blood samples to better understand HLH and find better ways to diagnose and treat it.
This trial tests a new drug called plonmarlimab for people with a rheumatic (joint or immune) disease who also have a dangerous overreaction of their immune system called HLH (or MAS). The goal is to see if the drug can help when high-dose steroids have not worked or are not an option.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.